The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer
Issued Date
2023-02-01
Resource Type
eISSN
20726694
Scopus ID
2-s2.0-85148998938
Journal Title
Cancers
Volume
15
Issue
4
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cancers Vol.15 No.4 (2023)
Suggested Citation
Tanjak P., Chaiboonchoe A., Suwatthanarak T., Acharayothin O., Thanormjit K., Chanthercrob J., Suwatthanarak T., Wannasuphaphol B., Chumchuen K., Suktitipat B., Sampattavanich S., Korphaisarn K., Pongpaibul A., Poungvarin N., Grove H., Riansuwan W., Trakarnsanga A., Methasate A., Pithukpakorn M., Chinswangwatanakul V. The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer. Cancers Vol.15 No.4 (2023). doi:10.3390/cancers15041098 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/81658
Title
The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer
Author(s)
Tanjak P.
Chaiboonchoe A.
Suwatthanarak T.
Acharayothin O.
Thanormjit K.
Chanthercrob J.
Suwatthanarak T.
Wannasuphaphol B.
Chumchuen K.
Suktitipat B.
Sampattavanich S.
Korphaisarn K.
Pongpaibul A.
Poungvarin N.
Grove H.
Riansuwan W.
Trakarnsanga A.
Methasate A.
Pithukpakorn M.
Chinswangwatanakul V.
Chaiboonchoe A.
Suwatthanarak T.
Acharayothin O.
Thanormjit K.
Chanthercrob J.
Suwatthanarak T.
Wannasuphaphol B.
Chumchuen K.
Suktitipat B.
Sampattavanich S.
Korphaisarn K.
Pongpaibul A.
Poungvarin N.
Grove H.
Riansuwan W.
Trakarnsanga A.
Methasate A.
Pithukpakorn M.
Chinswangwatanakul V.
Author's Affiliation
Other Contributor(s)
Abstract
Colorectal cancers (CRC) with KRAS mutations (KRASmut) are frequently included in consensus molecular subtype 3 (CMS3) with profound metabolic deregulation. We explored the transcriptomic impact of KRASmut, focusing on the tumor microenvironment (TME) and pathways beyond metabolic deregulation. The status of KRASmut in patients with CRC was investigated and overall survival (OS) was compared with wild-type KRAS (KRASwt). Next, we identified CMS, and further investigated differentially expressed genes (DEG) of KRASmut and distinctive pathways. Lastly, we used spatially resolved gene expression profiling to define the effect of KRASmut in the TME regions of CMS3-classified CRC tissues. CRC patients with KRASmut were mainly enriched in CMS3. Their specific enrichments of immune gene signatures in immunosuppressive TME were associated with worse OS. Activation of TGFβ signaling by KRASmut was related to reduced pro-inflammatory and cytokine gene signatures, leading to suppression of immune infiltration. Digital spatial profiling in TME regions of KRASmut CMS3-classified tissues suggested up-regulated genes, CD40, CTLA4, ARG1, STAT3, IDO, and CD274, that could be characteristic of immune suppression in TME. This study may help to depict the complex transcriptomic profile of KRASmut in immunosuppressive TME. Future studies and clinical trials in CRC patients with KRASmut should consider these transcriptional landscapes.